58333-75-8

Basic information

• Product Name: 4-(2-METHOXYPHENYL)PIPERIDINE
• Synonyms: 4-(2-METHOXYPHENYL)PIPERIDINE;2-(Piperidin-4-yl)anisole;Piperidine,4-(2-methoxyphenyl)-;4-(2-Methoxyphenyl)
• CAS NO: 58333-75-8
• Molecular Formula: C₁₂H₁₇NO
• Molecular Weight: 191.27
• Mol File: 58333-75-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 54 °C
• Boiling Point: 290.9 °C at 760 mmHg
• Flash Point: 117.7 °C
• Appearance: /
• Density: 1.003 g/cm³
• Vapor Pressure: 0.00201mmHg at 25°C
• Refractive Index: 1.515
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.22±0.10(Predicted)
• CAS DataBase Reference: 4-(2-METHOXYPHENYL)PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-METHOXYPHENYL)PIPERIDINE(58333-75-8)
• EPA Substance Registry System: 4-(2-METHOXYPHENYL)PIPERIDINE(58333-75-8)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38-52/53
• Safety Statements: 26-36/37/39-61
• Hazardous Substances Data: 58333-75-8(Hazardous Substances Data)

Usage

General Description

4-(2-Methoxyphenyl)piperidine, also known as 2-MeO-Diphenidine, is a chemical compound that belongs to the piperidine class. It is a derivative of Diphenidine, which is a dissociative anesthetic and hallucinogen. 4-(2-Methoxyphenyl)piperidine has been studied for its potential therapeutic applications in treating neurodegenerative disorders and depression, as well as its effects on the central nervous system. However, it is also considered to have potential for misuse and abuse due to its psychoactive properties. The compound is known to act as a selective NMDA receptor antagonist, leading to its potential biological and pharmacological effects. However, it is important to note that the compound's legal status and availability may vary in different jurisdictions, and its use should be carefully evaluated and regulated.

InChI:InChI=1/C12H17NO/c1-14-12-5-3-2-4-11(12)10-6-8-13-9-7-10/h2-5,10,13H,6-9H2,1H3

Upstream product

• 138647-49-1 4-Trifluoromethanesulfonyloxy-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester 
• 16750-63-3 2-methoxyphenylmagnesium bromide 
• 154422-95-4 1,2,3,6-tetrahydro-4-(2-methoxyphenyl)pyridine 
• 201609-28-1 1-t-Butoxycarbonyl-4-hydroxy-4-(2-methoxyphenyl)piperidine 
• 194669-41-5 1-t-Butoxycarbonyl-4-(2-methoxyphenyl)-1,2,3,6-tetrahydropyridine 
• 113411-59-9 1-benzyl-4-(2-methoxyphenyl)-1,2,3,6-tetrahydro-pyridine 
• 135-02-4 ortho-anisaldehyde 
• 105338-50-9 3-(2-methoxyphenyl)pentanedioic acid 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 5720-06-9 2-Methoxyphenylboronic acid 
• 201609-29-2 1-t-Butoxycarbonyl-4-(2-methoxyphenyl)piperidine 
• 100192-56-1 3-(2-Methoxy-phenyl)-glutarsaeureimid 

Downstream Products

• 161609-76-3 4-(2-hydroxyphenyl)-piperidine 
• 412302-13-7 N,N-dimethyl-2,2-diphenyl-4-[4-(2-hydroxyphenyl)piperidin-1-yl]butanamide 
• 412302-22-8 2-[2-[1-[4-(dimethylamino)-3,3-diphenyl-4-oxobutyl]piperidin-4-yl]phenoxy]ethyl acetate 
• 412302-21-7 ethyl [2-[1-[4-(dimethylamino)-3,3-diphenyl-4-oxobutyl]piperidin-4-yl]phenoxy]acetate 
• 474710-94-6 6-bromo-4-[4-(2-methoxyphenyl)piperidin-1-yl]quinazoline 
• 478179-18-9 2,4-bis-(2-hydroxy-ethylamino)-6-[4-(2-methoxy-phenyl)-piperidin-1-yl]-pyrimidine-5-carbonitrile 
• 1029402-08-1 C₃₀H₃₄N₄O₅ 
• 1376334-48-3 8-chloro-3-(cyclopropylmethyl)-7-[4-(2-methoxyphenyl)-1-piperidinyl]-1,2,4-triazolo[4,3-a]pyridine 
• 1552303-62-4 C₂₇H₃₆BrNO₃ 
• 1616294-18-8 2-cyclopropyl-6,7-dimethoxy-4-[4-(2-methoxy-phenyl)-piperidin-1-yl]-quinazoline 

Relevant articles and documents

2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS

Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.

Successful reduction of off-target hERG toxicity by structural modification of a T-type calcium channel blocker

To obtain an optimized T-type calcium channel blocker with reduced off-target hERG toxicity, we modified the structure of the original compound by introducing a zwitterion and reducing the basicity of the nitrogen. Among the structurally modified compound

Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging

The synthesis and in vitro and in vivo evaluation of a new series of 7-(phenylpiperidinyl)-1,2,4-triazolo[4,3-a]pyridines, which were conveniently radiolabeled with carbon-11, as potential positron emission tomography (PET) radiotracers for in vivo imagin